RSC Chapter: Role of Tau Aggregation Inhibitor Therapy in AD
Jul 01 - 2010 07:34 AM
TauRx has a new publication reviewing the role of Tau Aggregation Inhibitor Therapy in Alzheimer's Disease.
TauRx enters collaborative R&D agreement with Bayer Schering Pharma
Jun 04 - 2010 01:45 AM
WisTa Laboratories Ltd.(a wholly owned subsidiary of TauRx Pharmaceuticals) has entered a collaborative R&D agreement with Bayer Schering Pharma AG, Germany that could redefine the way Alzheimer's disease and related disorders are currently being diagnosed and treated.
TauRx to Present at Jefferies 2010 Global Life Sciences Conference
Jun 02 - 2010 01:35 AM
Professor Claude Wischik, Co-founder and Executive Chairman of TauRx, will present at the Jefferies 2010 Global Life Sciences Conference in New York on June 9th, 2010.
April 2010 Announcement: Phase 3 Trials
Apr 02 - 2010 01:52 AM
Following the appointment of Dr. Hans Moebius as Chief Medical Officer, TauRx has undertaken a competitive bid and review process to identify the most suitable partner to take forward its Phase 3 program.
March 2010 Announcement
Mar 11 - 2010 02:03 AM
TauRx Pharmaceuticals Group Company, WisTa Laboratories Ltd, has been notified by the European Patent Office that they are willing to grant a patent for a group of second-generation rember® derivatives discovered by and under development at the Company.